ISSN:
1432-1041
Keywords:
cromakalim
;
renin release
;
juxtaglomerular cells
;
membrane potential
;
hyperpolarisation
;
potassium channels
;
angiotensin II
;
norepinephrine
Source:
Springer Online Journal Archives 1860-2000
Topics:
Chemistry and Pharmacology
,
Medicine
Notes:
Summary The cardiovascular and endocrine profile of cromakalim has been studied in 8 healthy men (age 25±2 years; X SEM) and its influence on renin release from cultured rat juxtaglomerular cells in vitro has also been examined. According to a double-blind, randomized sequence the subjects received placebo or cromakalim 1 mg as a single daily oral dose for 5 days. Compared to placebo, cromakalim significantly increased plasma renin activity (+122%; from 1.73 to 3.87 ng AI·ml−1·h−1), angiotensin II (+105%; from 5.1 to 10.5 pg·ml−1), and norepinephrine (+61%) levels, and heart rate (+8%). Plasma aldosterone, blood pressure and indices of the electrolyte-fluid volume state were unchanged. Cromakalim in vitro stimulated renin release, from 9.9 to 36.5 ng AI·h−1·30 min·mg cell protein, from juxtaglomerular cells. It appears that the presumed K+-channel activator cromakalim increases renin release in vivo at least in part by direct stimulation of renal juxtaglomerular cells.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00558067
Permalink
